Algeta elects US experienced pharma industry executives Judith Hemberger and Kapil Dhingra to its Board of Directors
(Thomson Reuters ONE) -
Oslo, Norway, 26 April 2010 - Algeta ASA (OSE:ALGETA), the focused oncology
company, is very pleased to announce that Dr. Judith Hemberger and Dr. Kapil
Dhingra were elected to its Board of Directors as Non-executive Directors at the
Company's annual general meeting held in Oslo on 22 April 2010.
Judith Hemberger, Ph.D. (age 62), is an experienced biotech industry executive
with more than 30 years' of global pharmaceutical and biotech industry
experience. Dr. Hemberger was a co-founder, Executive Vice President and Chief
Operating Officer of Pharmion Corporation since its inception in 2000 until
2006. Prior to that, she served as Senior Vice President of Business Development
at AVAX Technologies, Inc., a vaccine technology company. From 1979 to 1998, Dr.
Hemberger worked in various capacities at Marion Laboratories, a pharmaceutical
company, and its successor companies Marion Merrell Dow and Hoechst Marion
Roussel, where she led a number of strategic functions including Professional
Education, Global Regulatory Affairs, Global Medical Affairs and Commercial
Development. Her final role at Hoechst Marion Roussel was Senior Vice President
of Global Drug Regulatory Affairs.
More recently, Dr Hemberger was a Venture Partner at Nomura Phase4 Ventures
(2006-2009) and Interim CEO of Zosano Pharma, Inc. She currently serves on the
board of directors of VasoGenix Pharmaceuticals, Inc. and Chroma Therapeutics,
and has previous board experience with Marion Merrell Dow, NexStar
Pharmaceuticals, Cell Pathways, Schein, Pharmion, PRA International, Perrigo,
Renovis, Myogen, Zosano Pharma, Novacea, Health Shares, Zymogenetics, and Atani.
Dr. Hemberger received a B.S. in biology and chemistry from Mount St.
Scholastica College (St. Benedictine College), a Ph.D. in Pharmacology from the
University of Missouri-Kansas City and an M.B.A. from Rockhurst College.
Kapil Dhingra M.B., B.S., (age 50), is formerly Vice President, Head, Oncology
Disease Biology Leadership Team, and Head, Oncology Clinical Development at
Hoffmann-La Roche, at which he worked between 1999-2008. For three years prior
to this, he worked as a Clinical and Senior Clinical Research Physician with Eli
Lilly and Company, and from 1989 to 1996 he was a Clinical Instructor, Assistant
Professor of Medicine at the University of Texas M.D. Anderson Cancer Center.
Throughout his industry career, Dr. Dhingra maintained an active faculty
appointment, initially at Indiana University School of Medicine from 1997 to
1999 as Clinical Associate Professor, and, more recently, at Memorial Sloan
Kettering Cancer Center in New York from 2000 to 2008.
Dr. Dhingra holds an M.B., B.S. degree (equivalent to a US M.D. degree) from the
All India Institute of Medical Sciences. In June 2008, Dr. Dhingra established
KAPital Consulting, LLC, a consulting company dedicated to assisting
biotechnology, pharmaceutical and diagnostic companies realize the full promise
of clinical and commercial advances in oncology. He is currently a board member
of Micromet, Inc., Coferon, Inc. (a privately held biotechnology company) and
the non-profit organization SARC (Sarcoma Alliance for Research Through
Collaboration).
Stein Annexstad, Chairman of Algeta, said: "We are very pleased to welcome Judy
and Kapil to the Algeta Board. Between them, they have a wealth of experience in
the US and global pharma industry and particularly in the clinical and
commercial development of innovative targeted cancer therapies. We look forward
to the valuable contributions they will make to the successful continued
development of Alpharadin, the building of our US commercial operations, and our
longer-term ambitions to develop the business via our thorium technology. We
would also like to thank Shahzad Malik, Inga Loen and Jens Petter Falck, who
stepped down from the Board at AGM, for their efforts and input over their
respective periods with the Company."
The new board of directors of Algeta consists of the following members: Stein
Annexstad (chairman), John E. Berriman (deputy chairman), Kapil Dhingra, Judith
Hemberger, Hilde Hermansen Steineger, Ingrid Wiik, Joe Anderson, and Per
Samuelsson.
###
For further information, please contact
Stein Annexstad, Chairman +47 90 77 02 77 (mob)
Andrew Kay, CEO +47 2300 7990 / +47 4840 1360 (mob)
Øystein Soug, CFO +47 2300 7990 / +47 9065 6525 (mob)
post(at)algeta.com
International media enquiries: +44 207 638 9571
Mark Swallow/Helena Galilee/David Dible mark.swallow(at)citigatedr.co.uk
Citigate Dewe Rogerson
US investor enquiries: +1 646 378 2928
Jessica Lloyd jlloyd(at)troutgroup.com
The Trout Group
About Algeta
Algeta is a focused oncology company developing novel targeted therapies for
patients with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (based on radium-223) is a first-in-class,
highly targeted alpha-pharmaceutical under clinical evaluation to improve
survival in patients with bone metastases from advanced cancer. Its localized
action helps preserve the surrounding healthy tissue thereby limiting
side-effects.
The development of bone metastases represents a serious development for cancer
patients as they are associated with a dramatic decline in patient health and
quality of life, ultimately leading to death. Bone metastases represent a major
unmet medical need, occurring in up to 90% of certain late-stage cancers, e.g.
prostate, breast and lung.
Alpharadin is partnered with Bayer Schering Pharma AG, a major pharmaceutical
company, and is in a global phase III clinical trial (ALSYMPCA) to treat bone
metastases resulting from hormone-refractory (castration-resistant) prostate
cancer. Alpharadin is also under investigation in phase II clinical trials as a
potential new treatment for bone metastases in endocrine-refractory breast
cancer patients.
Algeta also aims to develop a future pipeline of tumor-targeting
alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227,
through selective in-licensing and/or acquiring innovative technologies and
tumor-targeting molecules.
The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta
listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. There are a number of
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Theses
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
###
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1407965]
Press release: http://hugin.info/134655/R/1407965/360853.pdf
Unternehmensinformation / Kurzprofil:
Datum: 26.04.2010 - 09:07 Uhr
Sprache: Deutsch
News-ID 19642
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 445 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta elects US experienced pharma industry executives Judith Hemberger and Kapil Dhingra to its Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
